Qelbree

Qelbree (Viloxazine Extended-Release): Overview
​Qelbree is a non-stimulant medication approved by the FDA in 2021 for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6–17 and later in adults. It offers an alternative to stimulant medications and is particularly beneficial for individuals with ADHD who may not tolerate stimulants well or have concerns about stimulant misuse.
Mechanism of Action
Viloxazine, the active ingredient in Qelbree, is a norepinephrine reuptake inhibitor (NRI). It increases the levels of norepinephrine in the brain by blocking its reuptake at the synapse, enhancing focus, attention, and emotional regulation. Additionally, viloxazine has some activity on serotonin receptors, which may contribute to its effects on mood and anxiety symptoms.

​Dosage
Qelbree is available in extended-release capsules, which can be swallowed whole or sprinkled on food.

1. Children (6–11 years):
   • Starting dose: 100 mg once daily.
   • Titration: Increase weekly by 100 mg.
   • Maximum dose: 400 mg/day.
2. Adolescents (12–17 years):
   • Starting dose: 200 mg once daily.
   • Titration: Increase weekly by 200 mg.
   • Maximum dose: 400 mg/day.
3. Adults:
   • Starting dose: 200 mg once daily.
   • Titration: Increase weekly by 200 mg.
   • Maximum dose: 600 mg/day.

Clinical Benefits

1. ADHD Symptom Control:
   • Reduces hyperactivity, impulsivity, and inattention.
   • Effective as monotherapy or adjunct therapy.
2. Non-Stimulant Advantages:
   • No risk of abuse or dependency.
   • May be preferred for individuals with a history of substance misuse.
3. Improvement in Co-occurring Conditions:
   • May alleviate symptoms of anxiety or mood disorders due to its serotonergic activity.

Prevalence of Side EffectsQelbree is generally well-tolerated, but side effects are possible, particularly during initial treatment or dose adjustments.

1. Common Side Effects (10-30%):
   • Sleepiness or fatigue.
   • Decreased appetite.
   • Irritability or mood swings.
   • Nausea or vomiting.
2. Less Common Side Effects (1-10%):
   • Dizziness.
   • Constipation.
   • Increased blood pressure (monitoring recommended).
3. Rare but Serious Side Effects (<1%):
   • Suicidal thoughts: Similar to other ADHD medications, there is a boxed warning for an increased risk of suicidal ideation, particularly in children and adolescents.
   • Severe allergic reactions (rash or difficulty breathing).

EfficacyClinical trials have shown Qelbree to significantly improve ADHD symptoms compared to placebo, with noticeable effects as early as the first week of treatment. It provides a gradual and sustained therapeutic effect without the peaks and troughs associated with stimulants.

SummaryQelbree is a promising non-stimulant ADHD medication offering effective symptom management with a favorable safety profile. It is a good option for individuals who are sensitive to stimulants or have concerns about substance misuse.